Literature DB >> 12551990

Effective vaccination against long-term gammaherpesvirus latency.

Scott A Tibbetts1, J Scott McClellan, Shivaprakash Gangappa, Samuel H Speck, Herbert W Virgin.   

Abstract

The fundamental question of whether a primed immune system is capable of preventing latent gammaherpesvirus infection remains unanswered. Recent studies showing that vaccination can reduce acute replication and short-term latency but cannot alter long-term latency further call into question the possibility of achieving sterilizing immunity against gammaherpesviruses. Using the murine gammaherpesvirus 68 (gammaHV68) system, we demonstrate that it is possible to effectively vaccinate against long-term latency. By immunizing mice with a gammaHV68 mutant virus that is deficient in its ability to reactivate from latency, we reduced latent infection of wild-type challenge virus to a level below the limit of detection. Establishment of latency was inhibited by vaccination regardless of whether mice were challenged intraperitoneally or intranasally. Passive transfer of antibody from vaccinated mice could partially reconstitute the effect, demonstrating that antibody is an important component of vaccination. These results demonstrate the potential of a memory immune response against gammaherpesviruses to alter long-term latency and suggest that limiting long-term latent infection in a clinically relevant situation is an attainable goal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551990      PMCID: PMC141097          DOI: 10.1128/jvi.77.4.2522-2529.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  MHC class II-specific T cells can develop in the CD8 lineage when CD4 is absent.

Authors:  E O Matechak; N Killeen; S M Hedrick; B J Fowlkes
Journal:  Immunity       Date:  1996-04       Impact factor: 31.745

2.  Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.

Authors:  L A Morrison; D M Knipe
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

3.  Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant.

Authors:  M R MacDonald; X Y Li; R M Stenberg; A E Campbell; H W Virgin
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells.

Authors:  S Ehtisham; N P Sunil-Chandra; A A Nash
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

5.  Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.

Authors:  L A Morrison; D M Knipe
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections.

Authors:  M T Heise; H W Virgin
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

7.  Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV).

Authors:  A D Wilson; M Shooshstari; S Finerty; P Watkins; A J Morgan
Journal:  Clin Exp Immunol       Date:  1996-02       Impact factor: 4.330

8.  Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68.

Authors:  K E Weck; M L Barkon; L I Yoo; S H Speck; I V Virgin HW
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

10.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  34 in total

1.  Immature and transitional B cells are latency reservoirs for a gammaherpesvirus.

Authors:  Carrie B Coleman; Michael S Nealy; Scott A Tibbetts
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Maintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes.

Authors:  Linda F van Dyk; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.

Authors:  James Scott McClellan; Scott A Tibbetts; Shivaprakash Gangappa; Kelly A Brett; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection.

Authors:  Rebecca L Sparks-Thissen; Douglas C Braaten; Scott Kreher; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.

Authors:  Tammy M Rickabaugh; Helen J Brown; DeeAnn Martinez-Guzman; Ting-Ting Wu; Leming Tong; Fuqu Yu; Steven Cole; Ren Sun
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics.

Authors:  Joshua J Obar; Douglas C Donovan; Sarah G Crist; Ondine Silvia; James P Stewart; Edward J Usherwood
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Dendritic cells loaded with tumor B cells elicit broad immunity against murine gammaherpesvirus 68 but fail to prevent long-term latency.

Authors:  Janet Weslow-Schmidt; Fang Ye; Stephanie S Cush; Kathleen A Stuller; Marcia A Blackman; Emilio Flaño
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 8.  Immune regulation of viral infection and vice versa.

Authors:  Herbert W Virgin
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  A replication-defective gammaherpesvirus efficiently establishes long-term latency in macrophages but not in B cells in vivo.

Authors:  Haiyan Li; Kazufumi Ikuta; John W Sixbey; Scott A Tibbetts
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.